News

Precigen Announces Positive Phase 1 Data for Off-the-Shelf PRGN-2009 AdenoVerse™ Immunotherapy Alone and in Combination with an Investigational Checkpoint Inhibitor in Patients with Recurrent/Metastatic HPV-associated Cancers

by

–  PRGN-2009 combined with an investigational checkpoint inhibitor resulted in a 30% ORR in patients with heavily pre-treated HPV-associated cancers that were naïve or resistant to checkpoint blockade with prolonged duration of responses – –  Recurrent/metastatic HPV-associated cancers (cervical, anal, oropharyngeal, etc.) are incurable by current therapies – –  PRGN-2009 was safe and well-tolerated with only Grade … Read more

Elevation Oncology Highlights First-in-Human Phase 1 SYSA1801 (EO-3021) Clinical Data to be Presented by Partner CSPC Pharmaceutical Group Limited at ASCO 2023

by

Initial data showed promising signs of efficacy, including a 47.1% ORR in patients with resistant/refractory gastric cancer expressing Claudin 18.2, with a well-tolerated safety profile Elevation Oncology on track to initiate Phase 1 clinical trial in the US in the second half of 2023 NEW YORK, June 3, 2023 /PRNewswire/ — Elevation Oncology, Inc. (Nasdaq: … Read more

Sanyou launches new European offices and continues to promote global business landscape

by

SHANGHAI, June 3, 2023 /PRNewswire/ — In May 2023, following the CIC Boston branch in US, Sanyou opens new offices in The Shard London and CIC Rotterdam respectively, to rapidly promote the globalization of business landscape. Headquartered in Shanghai China, Sanyou Biopharmaceuticals Co., Ltd. is a world-leading national high-tech biotechnology enterprise focusing on R&D and services … Read more

Intensity Therapeutics’ INT230-6 Prolongs Survival Alone or in Combination With Ipilimumab in Adult Patients with Relapsed, Refractory, Metastatic Sarcomas

by

Compared To Synthetic Controls, INT230-6 Alone Extended Survival In Refractory Soft Tissue Sarcoma Subjects by Nearly 450 Days With Favorable Safety INT230-6, a Locally Delivered Cytotoxic Treatment Leading to a Systemic Immune Response in Hot or Cold Tumors, Is A New Way To Treat Sarcoma Results to be Presented Today, June 3, at the 2023 … Read more

High Schooler empowers Youth with Nonprofit “Unlimited Potential”, raises $100,000 for Sports Medicine Research and Advocacy

by

SEATTLE, June 3, 2023 /PRNewswire/ — Research indicates that approximately 3.5 million children under the age of 14 in North America do not participate in sports due to physical disabilities, genetic disorders, or other chronic health conditions. Unlimited Potential envisions a world where children facing challenges have the tools to overcome them, fostering an inclusive … Read more

Gas-propelled Devices are Expected to be Fastest Growing Segment

by

DUBLIN, June 2, 2023 /PRNewswire/ — The “Mucosal Atomization Devices Market – Growth, Trends, and Forecasts (2023 – 2028)” report has been added to ResearchAndMarkets.com’s offering. The mucosal atomization devices market is projected to record a CAGR of nearly 7.25% over the forecast period. Companies Mentioned  Teleflex Incorporated DeVilbiss Healthcare LLC Becton, Dickinson and Company Cook … Read more

Rising Prevalence of Respiratory and Other Associated Diseases Drives Growth

by

DUBLIN, June 2, 2023 /PRNewswire/ — The “Inhaled Nitric Oxide Market – Growth, Trends, COVID-19 Impact, and Forecasts (2023-28)” report has been added to  ResearchAndMarkets.com’s offering. The inhaled nitric oxide market is expected to register a CAGR of nearly 4.6% during the forecast period. Companies Mentioned  Air Liquide Healthcare BOC Healthcare Matheson Tri-Gas Inc. Merck KGaA … Read more

Increasing Prevalence of Chronic Disease Drives Growth

by

DUBLIN, June 2, 2023 /PRNewswire/ — The “Autoinjectors Global Market Report 2023” report has been added to  ResearchAndMarkets.com’s offering. This report provides strategists, marketers and senior management with the critical information they need to assess the market. The global autoinjectors market grew from $2.47 billion in 2022 to $3.01 billion in 2023 at a compound annual … Read more

Invivoscribe s’associe à Complete Genomics pour développer et commercialiser des tests de biomarqueurs pour l’oncologie et la recherche sur le cancer USA – Français USA – English India – English Latin America – español USA – español Brazil – Português USA – Deutsch

by

SAN DIEGO et SAN JOSÉ, Californie, 3 juin 2023 /PRNewswire/ — Invivoscribe et Complete Genomics ont annoncé aujourd’hui avoir conclu un partenariat pour développer et commercialiser des tests de biomarqueurs sur les plateformes NGS de Complete Genomics. Le territoire est mondial et les domaines sont l’oncologie et la recherche sur le cancer. Selon les termes de l’accord, Invivoscribe … Read more

Rising Prevalence of Diabetes Fuels the Sector

by

DUBLIN, June 2, 2023 /PRNewswire/ — The “Hemoglobin A1c Testing Devices Global Market Report 2023” report has been added to  ResearchAndMarkets.com’s offering. This report provides strategists, marketers and senior management with the critical information they need to assess the market. The global hemoglobin A1c testing devices market is expected to grow from $1.54 billion in 2022 … Read more